Advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma
Conditions
Interventions
Single arm group:medical treatement
Sponsors
Sanmenxia Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years old, no gender limit; 2. Patients with advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma confirmed by histology or cytology; 3. There is no serious liver and kidney damage, and the functional level of the organs must meet the following requirements: ANC >= 1.5x10^9/L; PLT >= 90x10^9/L; Hb >= 90 g/L; TBIL = 50 mL/min (Cockcroft-Gault formula); LVEF >= 50%; QT interval (QTcF) corrected by Fridericia method = 3 months; 7. The investigator assesses that the patient can comply with the requirements of the protocol; 8. Sign the informed consent document.
Exclusion criteria
Exclusion criteria: 1. Hypertension patients who have been treated with a variety of antihypertensive drugs but are still difficult to control (systolic blood pressure >= 160 mmHg and diastolic blood pressure >= 90 mmHg); 2. Patients with acute coronary syndrome (including myocardial infarction and unstable angina) and a history of coronary angioplasty or stent placement within 6 months before enrollment; 3. Patients with a large amount of pleural effusion or ascites requiring drainage; 4. Patients with partial or complete gastrointestinal obstruction; 5. According to the judgment of the investigator, the abnormal blood coagulation function has clinical significance, has a bleeding tendency or is receiving thrombolysis or anticoagulation therapy; 6. Women who are pregnant or breastfeeding, have fertility but refuse to take contraceptive measures; 7. According to the judgment of the investigator, there are concomitant diseases (diabetes, thyroid disease, etc.) that seriously endanger the safety of the patient or affect the completion of the study; 8. Patients with unhealed wounds, unhealed ulcers or unhealed fractures; 9. Patients who are allergic to apatinib mesylate tablets and/or its excipients; 10. The investigator judges other situations that are not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;1-year overall survival;2-year overall survival;objective response rate;disease control rate; | — |
Countries
China
Contacts
Public ContactTian Chuntao
Sanmenxia Central Hospital
Outcome results
None listed